Chimeric antigen receptor-modified T-cells targeting CD19 (CAR-T19) are licensed for treating relapsed/refractory diffuse large B-cell lymphoma and B-acute lymphoblastic leukemia. Predicting treatment responses and toxicity (e.g., cytokine release syndrome and neurotoxicity) remains a big challenge. CAR-T19 monitoring could increase our understanding of treatment responses and be of relevance to patient management. A robust method for accurate CAR-T19 detection is therefore extremely desirable.

中文翻译：

---

外周血和脑脊液中 CAR-T19 细胞的检测：适用于常规诊断实验室的检测

靶向 CD19 (CAR-T19) 的嵌合抗原受体修饰 T 细胞获准用于治疗复发/难治性弥漫性大 B 细胞淋巴瘤和 B 急性淋巴细胞白血病。预测治疗反应和毒性（例如，细胞因子释放综合征和神经毒性）仍然是一个巨大的挑战。CAR-T19监测可以增加我们对治疗反应的理解，并与患者管理相关。因此，非常需要一种用于准确检测 CAR-T19 的稳健方法。